Myopia Medications
Clinical practitioners and researchers continue to look for more beneficial approaches to prevent myopia from getting worse over time. Therefore, the therapies that reveal the most swear to date consist of:
- The current medication, atropine: Recent atropine drops are most commonly utilized to lubricate the pupil of the eye, sometimes as part of an eye examination or after or before eye surgery. Atropine eye drops in different doses might also aid in lowering the development of nearsightedness. The accurate mechanism for such an effect is still not known. There has been a wide research on the utilization of atropine in the cure of nearsightedness progression. Atropine is not a selective muscarinic antagonist idea to work on the five muscarinic receptor subtypes in an eye of a human, stop glycosaminoglycan synthesis in scleral fibroblasts, and M1 by M5.
- In addition, it has been considered that, such as light, atropine regulates the parasympathetic nervous system by the five muscarinic receptor sub kinds present on the iris sphincter of the human, ciliary body and even though by the sclera, retina, and lens. Not just atropine is thought to perform on the muscarinic receptors in an eye directly, but it is also thought to lower or increase the amount of the receptor.
- Increasing time outdoors: Spending time outside while adolescence and your early adulthood might lower the lifetime chance of having nearsightedness. Researchers assume that the sun’s ultraviolet (UV) rays exposure might alter the molecular shape of the cornea and sclera and aid in maintaining a normal structure.
- Orthokeratology: In this method, you wear hard, gas penetrable contact lenses for so many hours per day till your eye curvature evens out. Then you wear your lenses sometimes to maintain the new structure. If you do not continue this treatment, your eye goes back to its former structure. There is proof that this lens does reduce the elongation of the eyeball nearsightedness that reduces myopia.
- Dual focus contact lenses: A new kind of dual-focus contact lens has been shown to reduce the formation of nearsightedness in children between the age of 8 and 12 years.
- Pirenzepine: Pirenzepine is a M1 selective muscarinic receptor antagonist. It is quite selective than atropine and however results in lower mydriasis and cycloplegia. It shows that 12-month utilization of 2% recent pirenzepine ophthalmic gel two times a day is linked with a 40 percent lowering in axial length. Unfortunately, pirenzepine gel is not available for commercial use. Further studies on the long-term efficacy and safety of pirenzepine are warranted still.
Various studies in the literature have been reporting that the use of atropine has delayed the myopia progression significantly and axial elongation. Atropine also reduces the regulation of inflammatory markers in your eye and seems to be involved in the progression of myopia. Therefore, myopia and its complication association are high public health concerns. While contact lenses and glasses correction is important in preventing the symptomatic vision alteration links with nearsightedness, they do not alter the anatomic development of the myopic eye. (9)